Diabetic macular oedema treated with intravitreal anti ‐vascular endothelial growth factor – 2–4 years follow‐up of visual acuity and retinal thickness in 566 patients following Danish national guidelines

ConclusionIn a single‐centre clinical setting, 566 patients treated for DME with ranibizumab according to the Danish national guidelines were followed for up to 4 years. Best‐corrected visual acuity (BCVA) outcomes are in the low end of clinical studies, but studied on a wider population and achieved with fewer injections.
Source: Acta Ophthalmologica - Category: Opthalmology Authors: Tags: Original Article Source Type: research